<code id='1AB0A24B92'></code><style id='1AB0A24B92'></style>
    • <acronym id='1AB0A24B92'></acronym>
      <center id='1AB0A24B92'><center id='1AB0A24B92'><tfoot id='1AB0A24B92'></tfoot></center><abbr id='1AB0A24B92'><dir id='1AB0A24B92'><tfoot id='1AB0A24B92'></tfoot><noframes id='1AB0A24B92'>

    • <optgroup id='1AB0A24B92'><strike id='1AB0A24B92'><sup id='1AB0A24B92'></sup></strike><code id='1AB0A24B92'></code></optgroup>
        1. <b id='1AB0A24B92'><label id='1AB0A24B92'><select id='1AB0A24B92'><dt id='1AB0A24B92'><span id='1AB0A24B92'></span></dt></select></label></b><u id='1AB0A24B92'></u>
          <i id='1AB0A24B92'><strike id='1AB0A24B92'><tt id='1AB0A24B92'><pre id='1AB0A24B92'></pre></tt></strike></i>

          Home / hotspot / hotspot

          hotspot


          hotspot

          author:entertainment    Page View:245
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In